Pancreatic neuroendocrine tumors (pNETs) are frequently malignant (50-80%, except for insulinoma) and may show an aggressive course with metastases to the liver as well as more distant sites. These heterogeneous neoplasms include functioning tumors, which secrete a variety of peptide hormones, and non-functioning tumors (up to 90% of pNETs), which often show metastases at the time of diagnosis.
Therapy for metastatic pancreatic neuroendocrine tumors / R.E. Rossi, S. Massironi, D. Conte, M. Peracchi. - In: ANNALS OF TRANSLATIONAL MEDICINE. - ISSN 2305-5839. - 2:1(2014 Jan), pp. 8.1-8.12. [10.3978/j.issn.2305-5839.2013.03.01]
Therapy for metastatic pancreatic neuroendocrine tumors
R.E. RossiPrimo
;S. MassironiSecondo
;D. ContePenultimo
;M. PeracchiUltimo
2014
Abstract
Pancreatic neuroendocrine tumors (pNETs) are frequently malignant (50-80%, except for insulinoma) and may show an aggressive course with metastases to the liver as well as more distant sites. These heterogeneous neoplasms include functioning tumors, which secrete a variety of peptide hormones, and non-functioning tumors (up to 90% of pNETs), which often show metastases at the time of diagnosis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1730-PB5-R4.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
245.62 kB
Formato
Adobe PDF
|
245.62 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
